A phase I/Ib study of OTSGC-A24 combined peptide vaccine in advanced gastric cancer

BACKGROUND: We conducted a phase I/Ib, open-label, single-arm trial to assess the safety, tolerability and optimal scheduling regimen of OTSGC-A24 cancer vaccine in patients with advanced gastric cancer. METHODS: Patients with advanced gastric cancer with HLA-A*24:02 haplotype were included in this...

Descripción completa

Detalles Bibliográficos
Autores principales: Sundar, Raghav, Rha, Sun Young, Yamaue, Hiroki, Katsuda, Masahiro, Kono, Koji, Kim, Hyo Song, Kim, Chan, Mimura, Kousaku, Kua, Ley-Fang, Yong, Wei Peng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5870101/
https://www.ncbi.nlm.nih.gov/pubmed/29587677
http://dx.doi.org/10.1186/s12885-018-4234-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5870101/
https://www.ncbi.nlm.nih.gov/pubmed/29587677
http://dx.doi.org/10.1186/s12885-018-4234-8

Ejemplares similares